We represented a global healthcare company regarding a drug diversion allegation that controlled substances were inappropriately ordered, secured and dispensed by the company in violation of state and federal law. After conducting an internal investigation into the allegations and meeting with the DEA, the government declined to pursue further action against our client.
Global Healthcare Company Faces Drug Diversion Allegations
You Also May Be Interested In:
Lead counsel representing emergency department provider and other defendants in qui tam lawsuit alleging violation of licensure laws caused submission of false claims. District court dismissed allegations against the emergency department provider on grounds that alleged regulatory violation did not satisfy standard for FCA materiality set forth in Supreme Court’s Escobar decision. U.S. ex rel. Taylor v. Boyko, 2019 WL 2423283 (S.D. W. Va. Jun. 6, 2019).
Successfully represented a private equity backed portfolio provider and its management company in a voluntary disclosure to HHS-OIG involving improper billing
Lead counsel for a large long-term care company named as a defendant in a FCA qui tam action involving allegations of medically unnecessary services and improper billing